# Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation

> **NCT07397351** · PHASE2 · RECRUITING · sponsor: **Research Institute of Geroprotective Technologies** · enrollment: 180 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Aroxxen

## Key facts

- **NCT ID:** NCT07397351
- **Lead sponsor:** Research Institute of Geroprotective Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07397351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07397351, "Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07397351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*